The present invention provides chimeric and humanized antibodies that specifically recognize .alpha.5.beta.1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.